Cargando…
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study
The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER family genes in early breast cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel. RNA was extracted from 268 formalin-fixed paraff...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600696/ https://www.ncbi.nlm.nih.gov/pubmed/18985033 http://dx.doi.org/10.1038/sj.bjc.6604769 |
_version_ | 1782162198512009216 |
---|---|
author | Koutras, A K Kalogeras, K T Dimopoulos, M-A Wirtz, R M Dafni, U Briasoulis, E Pectasides, D Gogas, H Christodoulou, C Aravantinos, G Zografos, G Timotheadou, E Papakostas, P Linardou, H Razis, E Economopoulos, T Kalofonos, H P Fountzilas, G |
author_facet | Koutras, A K Kalogeras, K T Dimopoulos, M-A Wirtz, R M Dafni, U Briasoulis, E Pectasides, D Gogas, H Christodoulou, C Aravantinos, G Zografos, G Timotheadou, E Papakostas, P Linardou, H Razis, E Economopoulos, T Kalofonos, H P Fountzilas, G |
author_sort | Koutras, A K |
collection | PubMed |
description | The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER family genes in early breast cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel. RNA was extracted from 268 formalin-fixed paraffin-embedded (FFPE) tumour tissue samples of high-risk breast cancer patients enrolled in the randomised HE10/97 trial, evaluating the effect of dose-dense anthracycline-based sequential adjuvant chemotherapy with or without paclitaxel. The mRNA expression of all four HER family members was assessed by kinetic reverse transcription-polymerase chain reaction (kRT–PCR). The overall concordance between kRT–PCR and IHC/FISH for HER2 status determination was 74%. At a median follow-up of 8 years, multivariate analysis showed that EGFR and HER2 mRNA expression was associated with reduced overall survival (OS). HER3 and HER4 mRNA level had a favourable prognostic value in terms of OS and disease-free survival (DFS), respectively. Adjusting for HER2 mRNA expression, OS and DFS did not differ between treatment groups. These data indicate that EGFR as well as HER2 are prognostic factors of worse clinical outcomes, whereas HER3 and HER4 gene transcription is associated with better prognosis in high-risk early breast cancer. However, HER2 mRNA expression did not predict clinical benefit from paclitaxel. Kinetic RT–PCR represents an alternative method for evaluating the expression of HER family members in FFPE breast carcinomas. |
format | Text |
id | pubmed-2600696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-26006962009-12-03 Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study Koutras, A K Kalogeras, K T Dimopoulos, M-A Wirtz, R M Dafni, U Briasoulis, E Pectasides, D Gogas, H Christodoulou, C Aravantinos, G Zografos, G Timotheadou, E Papakostas, P Linardou, H Razis, E Economopoulos, T Kalofonos, H P Fountzilas, G Br J Cancer Clinical Study The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER family genes in early breast cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel. RNA was extracted from 268 formalin-fixed paraffin-embedded (FFPE) tumour tissue samples of high-risk breast cancer patients enrolled in the randomised HE10/97 trial, evaluating the effect of dose-dense anthracycline-based sequential adjuvant chemotherapy with or without paclitaxel. The mRNA expression of all four HER family members was assessed by kinetic reverse transcription-polymerase chain reaction (kRT–PCR). The overall concordance between kRT–PCR and IHC/FISH for HER2 status determination was 74%. At a median follow-up of 8 years, multivariate analysis showed that EGFR and HER2 mRNA expression was associated with reduced overall survival (OS). HER3 and HER4 mRNA level had a favourable prognostic value in terms of OS and disease-free survival (DFS), respectively. Adjusting for HER2 mRNA expression, OS and DFS did not differ between treatment groups. These data indicate that EGFR as well as HER2 are prognostic factors of worse clinical outcomes, whereas HER3 and HER4 gene transcription is associated with better prognosis in high-risk early breast cancer. However, HER2 mRNA expression did not predict clinical benefit from paclitaxel. Kinetic RT–PCR represents an alternative method for evaluating the expression of HER family members in FFPE breast carcinomas. Nature Publishing Group 2008-12-02 2008-11-04 /pmc/articles/PMC2600696/ /pubmed/18985033 http://dx.doi.org/10.1038/sj.bjc.6604769 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Koutras, A K Kalogeras, K T Dimopoulos, M-A Wirtz, R M Dafni, U Briasoulis, E Pectasides, D Gogas, H Christodoulou, C Aravantinos, G Zografos, G Timotheadou, E Papakostas, P Linardou, H Razis, E Economopoulos, T Kalofonos, H P Fountzilas, G Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study |
title | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study |
title_full | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study |
title_fullStr | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study |
title_full_unstemmed | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study |
title_short | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study |
title_sort | evaluation of the prognostic and predictive value of her family mrna expression in high-risk early breast cancer: a hellenic cooperative oncology group (hecog) study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600696/ https://www.ncbi.nlm.nih.gov/pubmed/18985033 http://dx.doi.org/10.1038/sj.bjc.6604769 |
work_keys_str_mv | AT koutrasak evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT kalogeraskt evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT dimopoulosma evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT wirtzrm evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT dafniu evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT briasoulise evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT pectasidesd evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT gogash evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT christodoulouc evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT aravantinosg evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT zografosg evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT timotheadoue evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT papakostasp evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT linardouh evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT razise evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT economopoulost evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT kalofonoshp evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy AT fountzilasg evaluationoftheprognosticandpredictivevalueofherfamilymrnaexpressioninhighriskearlybreastcancerahelleniccooperativeoncologygrouphecogstudy |